AMY HAYES: Open Payments
NPI 1427220169 · ROCHESTER, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,404 in 184 payments from 21 companies in 2025. Trend: 2023 $2,238 · 2024 $3,568 · 2025 $3,404
Food & beverage: $3,317Education: $87
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. | 21 | $522 |
| ABBVIE INC. | 24 | $447 |
| Takeda Pharmaceuticals U.S.A., Inc. | 20 | $342 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 33 | $324 |
| Phathom Pharmaceuticals, Inc. | 19 | $300 |
| Madrigal Pharmaceuticals | 6 | $281 |
| Ardelyx, Inc. | 8 | $176 |
| Lilly USA, LLC | 14 | $172 |
| GENZYME CORPORATION | 8 | $166 |
| Regeneron Healthcare Solutions, Inc. | 5 | $117 |
Products named: TREMFYA, XIFAXAN, RINVOQ, VOQUEZNA, REZDIFFRA, DUPIXENT, ENTYVIO, IBSRELA.
Industry payments across NY — which companies pay providers there.
